Over The Counter (OTC) Drugs Market Report by Product Type (Cough, Cold and Flu Products, Analgesics, Dermatology Products, Gastrointestinal Products, Vitamins, Minerals and Supplements (VMS), Weight-loss/Dietary Products, Ophthalmic Products, Sleeping Aids, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Dosage Form (Tablets and Capsules, Liquids, Ointments, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2024-2032
The global over the counter (OTC) drugs market size reached US$ 168.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 275.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.5% during 2024-2032.
Over the counter (OTC) drugs, also known as non-prescription drugs, can be used without a prescription or the need for seeking treatment by a healthcare professional. They are safe and effective and help cure pain, cough and cold, diarrhea, constipation, acne and manage recurring migraines and allergies. They are currently available in pharmacies, convenience stores, supermarkets and gas stations across the globe.
Over The Counter (OTC) Drugs Market Trends:
The increasing utilization of OTC drugs to treat minor ailments among individuals represents one of the key factors bolstering the market growth. Besides this, OTC medications, such as antacids, histamine-2 (H2) blockers, and proton pump inhibitors (PPIs), are used to relieve and prevent heartburn or acid indigestion. In addition, due to the coronavirus disease (COVID-19) outbreak, there is a rise in awareness among individuals about the importance of self-care. This, in turn, is increasing the sales of nutritional supplements and strengthening the market growth. Moreover, key players are expanding their product portfolio to widen their consumer base and increase their geographical presence. This, coupled with the increasing approvals from regulatory bodies for switching prescription drugs to OTC drugs, is positively influencing the market. Apart from this, there is currently an increase in the number of people opting for OTC drugs rather than consulting physicians on account of increasing healthcare costs. Furthermore, self-medication practices can assist in controlling chronic diseases, reducing absenteeism from work, and saving scarce medical resources from being exhausted during minor conditions. Some of the other factors, such as the rising geriatric population worldwide, rapid expansion of distribution channels, and significant growth in the pharmaceutical industry, are driving the overall sales and profitability.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global over the counter (OTC) drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, route of administration, dosage form, and distribution channel.
Breakup by Product Type:
Cough, Cold and Flu Products
Analgesics
Dermatology Products
Gastrointestinal Products
Vitamins, Minerals and Supplements (VMS)
Weight-loss/Dietary Products
Ophthalmic Products
Sleeping Aids
Others
Breakup by Route of Administration:
Oral
Parenteral
Topical
Others
Breakup by Dosage Form:
Tablets and Capsules
Liquids
Ointments
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Alkem Laboratories Limited, Bayer AG, Daiichi Sankyo Company Limited, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Perrigo Company plc, Pfizer Inc., Piramal Enterprises Ltd., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
1. What was the size of the global over the counter (OTC) drugs market in 2023?
2. What is the expected growth rate of the global over the counter (OTC) drugs market during 2024-2032?
3. What are the key factors driving the global over the counter (OTC) drugs market?
4. What has been the impact of COVID-19 on the global over the counter (OTC) drugs market?
5. What is the breakup of the global over the counter (OTC) drugs market based on the product type?
6. What is the breakup of the global over the counter (OTC) drugs market based on the route of administration?
7. What is the breakup of the global over the counter (OTC) drugs market based on the dosage form?
8. What is the breakup of the global over the counter (OTC) drugs market based on the distribution channel?
9. What are the key regions in the global over the counter (OTC) drugs market?
10. Who are the key players/companies in the global over the counter (OTC) drugs market?
Over the counter (OTC) drugs, also known as non-prescription drugs, can be used without a prescription or the need for seeking treatment by a healthcare professional. They are safe and effective and help cure pain, cough and cold, diarrhea, constipation, acne and manage recurring migraines and allergies. They are currently available in pharmacies, convenience stores, supermarkets and gas stations across the globe.
Over The Counter (OTC) Drugs Market Trends:
The increasing utilization of OTC drugs to treat minor ailments among individuals represents one of the key factors bolstering the market growth. Besides this, OTC medications, such as antacids, histamine-2 (H2) blockers, and proton pump inhibitors (PPIs), are used to relieve and prevent heartburn or acid indigestion. In addition, due to the coronavirus disease (COVID-19) outbreak, there is a rise in awareness among individuals about the importance of self-care. This, in turn, is increasing the sales of nutritional supplements and strengthening the market growth. Moreover, key players are expanding their product portfolio to widen their consumer base and increase their geographical presence. This, coupled with the increasing approvals from regulatory bodies for switching prescription drugs to OTC drugs, is positively influencing the market. Apart from this, there is currently an increase in the number of people opting for OTC drugs rather than consulting physicians on account of increasing healthcare costs. Furthermore, self-medication practices can assist in controlling chronic diseases, reducing absenteeism from work, and saving scarce medical resources from being exhausted during minor conditions. Some of the other factors, such as the rising geriatric population worldwide, rapid expansion of distribution channels, and significant growth in the pharmaceutical industry, are driving the overall sales and profitability.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global over the counter (OTC) drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, route of administration, dosage form, and distribution channel.
Breakup by Product Type:
Cough, Cold and Flu Products
Analgesics
Dermatology Products
Gastrointestinal Products
Vitamins, Minerals and Supplements (VMS)
Weight-loss/Dietary Products
Ophthalmic Products
Sleeping Aids
Others
Breakup by Route of Administration:
Oral
Parenteral
Topical
Others
Breakup by Dosage Form:
Tablets and Capsules
Liquids
Ointments
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Alkem Laboratories Limited, Bayer AG, Daiichi Sankyo Company Limited, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Perrigo Company plc, Pfizer Inc., Piramal Enterprises Ltd., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
1. What was the size of the global over the counter (OTC) drugs market in 2023?
2. What is the expected growth rate of the global over the counter (OTC) drugs market during 2024-2032?
3. What are the key factors driving the global over the counter (OTC) drugs market?
4. What has been the impact of COVID-19 on the global over the counter (OTC) drugs market?
5. What is the breakup of the global over the counter (OTC) drugs market based on the product type?
6. What is the breakup of the global over the counter (OTC) drugs market based on the route of administration?
7. What is the breakup of the global over the counter (OTC) drugs market based on the dosage form?
8. What is the breakup of the global over the counter (OTC) drugs market based on the distribution channel?
9. What are the key regions in the global over the counter (OTC) drugs market?
10. Who are the key players/companies in the global over the counter (OTC) drugs market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL OVER THE COUNTER (OTC) DRUGS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT TYPE
6.1 Cough, Cold and Flu Products
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Analgesics
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Dermatology Products
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Gastrointestinal Products
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Vitamins, Minerals and Supplements (VMS)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Weight-loss/Dietary Products
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Ophthalmic Products
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Sleeping Aids
6.8.1 Market Trends
6.8.2 Market Forecast
6.9 Others
6.9.1 Market Trends
6.9.2 Market Forecast
7 MARKET BREAKUP BY ROUTE OF ADMINISTRATION
7.1 Oral
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Parenteral
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Topical
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY DOSAGE FORM
8.1 Tablets and Capsules
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Liquids
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Ointments
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 MARKET BREAKUP BY DISTRIBUTION CHANNEL
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 MARKET BREAKUP BY REGION
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT ANALYSIS
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 VALUE CHAIN ANALYSIS
13 PORTERS FIVE FORCES ANALYSIS
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 PRICE ANALYSIS
15 COMPETITIVE LANDSCAPE
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Alkem Laboratories Limited
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Bayer AG
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Daiichi Sankyo Company Limited
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Dr. Reddy’s Laboratories Ltd.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 GlaxoSmithKline plc
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Johnson & Johnson
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Novartis AG
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Perrigo Company plc
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Pfizer Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Piramal Enterprises Ltd.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.11 Reckitt Benckiser Group PLC
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Sanofi S.A.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
15.3.13 Sun Pharmaceutical Industries Ltd.
15.3.13.1 Company Overview
15.3.13.2 Product Portfolio
15.3.13.3 Financials
15.3.13.4 SWOT Analysis
15.3.14 Teva Pharmaceutical Industries Ltd.
15.3.14.1 Company Overview
15.3.14.2 Product Portfolio
15.3.14.3 Financials
15.3.14.4 SWOT Analysis
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL OVER THE COUNTER (OTC) DRUGS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT TYPE
6.1 Cough, Cold and Flu Products
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Analgesics
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Dermatology Products
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Gastrointestinal Products
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Vitamins, Minerals and Supplements (VMS)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Weight-loss/Dietary Products
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Ophthalmic Products
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Sleeping Aids
6.8.1 Market Trends
6.8.2 Market Forecast
6.9 Others
6.9.1 Market Trends
6.9.2 Market Forecast
7 MARKET BREAKUP BY ROUTE OF ADMINISTRATION
7.1 Oral
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Parenteral
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Topical
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY DOSAGE FORM
8.1 Tablets and Capsules
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Liquids
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Ointments
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 MARKET BREAKUP BY DISTRIBUTION CHANNEL
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 MARKET BREAKUP BY REGION
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT ANALYSIS
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 VALUE CHAIN ANALYSIS
13 PORTERS FIVE FORCES ANALYSIS
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 PRICE ANALYSIS
15 COMPETITIVE LANDSCAPE
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Alkem Laboratories Limited
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Bayer AG
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Daiichi Sankyo Company Limited
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Dr. Reddy’s Laboratories Ltd.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 GlaxoSmithKline plc
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Johnson & Johnson
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Novartis AG
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Perrigo Company plc
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Pfizer Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Piramal Enterprises Ltd.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.11 Reckitt Benckiser Group PLC
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Sanofi S.A.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
15.3.13 Sun Pharmaceutical Industries Ltd.
15.3.13.1 Company Overview
15.3.13.2 Product Portfolio
15.3.13.3 Financials
15.3.13.4 SWOT Analysis
15.3.14 Teva Pharmaceutical Industries Ltd.
15.3.14.1 Company Overview
15.3.14.2 Product Portfolio
15.3.14.3 Financials
15.3.14.4 SWOT Analysis
